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Cancer is one of the most lethal diseases. By 2030, deaths caused by cancers are estimated to
reach 13 million per year worldwide. Cancer is a collection of related diseases distinguished
by uncontrolled cell division that is driven by genomic alterations. Cancer is heterogeneous
and shows an extraordinary genomic diversity between patients with transcriptionally and
histologically similar cancer subtypes, and even between tumors from the same anatomical
position. The heterogeneity poses great challenges in understanding cancer mechanisms and
drug resistance; this understanding is critical for precise prognosis and improved treatments.
Emergence of high-throughput technologies, such as microarrays and next-generation se-
quencing, has motivated the investigation of cancer cells on a genome-wide scale. Over the
last decade, an unprecedented amount of high-throughput data has been generated. The chal-
lenge is to turn such a vast amount of raw data into clinically valuable information to benefit
cancer patients. Single omics data have failed to fully uncover mechanisms behind cancer
phenotypes. Accordingly, integrative approaches have been introduced to systematically
analyze and interpret multi-omics data, among which network-based integrative approaches
have achieved substantial advances in basic biological studies and cancer treatments.
In this thesis, the development and application of network-based integrative methods are in-
cluded to address challenges in analyzing cancer samples. Two novel methods are introduced
to integrate disparate omics data and biological networks at the single-patient level: PerPAS,
which takes pathway topology into account and integrates gene expression and clinical
data with pathway information; and DERA, which elevates gene expression analysis to the
network level and identifies network-based biomarkers that provide functional interpretation.
The performance of both methods was demonstrated using biological experiment data, and
the results were validated in independent cohorts.
The application part of this thesis focuses on understanding cancer mechanisms and identify-
ing clinical biomarkers in breast cancer and diffuse large B-cell lymphoma using PerPAS,
DERA, and an existing method SPIA. Our experimental results provided insights into under-
lying cancer mechanisms and potential prognostic biomarkers for breast cancer, and identified
therapeutic targets for diffuse large B-cell lymphoma. The potential of the therapeutic targets
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We live in an increasingly connected world. Our connections, friends, neighbors,
and colleagues indicate who we are, what we do, and how influential we are.
Increase of connections in volume challenges advanced use of such information,
which requires efficient representation. Network representation is a collection of
connections and is useful to visualize and analyze complex systems. Network
analysis can provide insights and improve interpretation. Accordingly, applications
of network analysis have emerged in various areas, such as mobile communication
networks [1] and biological networks [2, 3].
Biological networks consist of numerous molecules, which interact with each
other and display highly diverse dynamics. The dynamics of biological networks,
which reflect cell conditions and environmental stimulation [4], are controlled and
coordinated by multiple levels of information, such as genetics and transcriptomics
[5]. Genetic information is known as the blueprint of life [6]. The transcriptome is
considered to be the central component in a cell [7], and a biological network is the
abstraction of complex logic in cells [8]. Compared to genetic and genomic data,
biological network data provide a number of advantages in aggregating molecular
events across network neighborhood or genes in the same pathway, thus improving
interpretation and comparability, and facilitating multi-omics data integration [8].
Multi-omics data integration is key to understanding biology [9] and has demon-
strated its potential in revealing disease mechanisms and identifying prognostic
markers and crucial molecules for targeted therapy [10, 11]. Such potential has been
driven by technological advancements that efficiently measure tens of thousands
of molecules simultaneously. A deluge of molecular data has been produced and
been made publicly available to accelerate the understanding of molecular biology,
especially molecular cancer biology. Consortia, such as The Cancer Genome
Atlas (TCGA) consortium [10], provide molecular and clinical data from tens of
thousands of cancer patients. However, such a massive amount of data has posed
challenges to data management, interpretation, and integration [12].
Cancer is one of the most lethal diseases, characterized by uncontrolled cellular
growth. Though survival of cancer patients has improved due to earlier diagnosis
[13], worldwide cancer fatalities were 8.2 million per year in 2012 and are predicted
to reach 13 million per year by 2030 [14]. Our understanding of cancer has grown
greatly due to the advancements of tools and combined research efforts from
multiple fields, such as biology, medicine, mathematics and computer science [7].
However, the heterogeneity of the cancer genome leads to drug resistance and other
challenges in cancer treatments.
1
1 INTRODUCTION
Many cancer subtypes have been identified [10, 11], enabling personalized treat-
ments [15, 16]. However, these discoveries have not managed to completely
stop patients from experiencing cancer progression, relapse, and metastasis. For
instance, breast cancer patients belonging to the human epidermal growth factor
receptor 2 (HER2) enriched subtype are treated with HER2 inhibitors, whereas
few beneficial therapies have been found for patients with the triple-negative breast
cancer (TNBC) subtype. TNBC tumors are usually larger in size, higher grade,
more aggressive, and have a higher risk of developing distant metastasis than the
other breast cancer subtypes [17]. Recent results show that there are substantial
differences among cancer samples that belong to similar subtypes [17, 18], which
calls for personalizing treatments based on data integration for individual patients.
The goal of this thesis was to study integrative analysis of transcriptomic data,
clinical data, and biological networks to understand cancer mechanisms and identify
clinical biomarkers in cancer. This thesis consists of two parts: development of
integrative analytical methods and their application. The development part aimed
to provide improved computational tools that facilitate a deeper understanding
of molecular mechanisms in cancer. The goals of the application part were to
advance understanding of cancer mechanisms, to identify prognostic markers
for predicting cancer progression, and to suggest crucial molecules for targeted
therapy. In addition to scientific publications (Publication I-III), unpublished results
demonstrated superior performance of our method in integrating multi-omics data.
2
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2 Molecular biology background
The central dogma of molecular biology was first described by Francis Crick in 1956
and later formalized in 1970 [19]. The central dogma of molecular biology states
sequential information transfer from genome to proteins (Figure 1). In essence,
genetic information contained in deoxyribonucleic acid (DNA) is transcribed into
messenger ribonucleic acid (mRNA) and is subsequently translated into proteins.
Most DNA is locally restricted to the cell nucleus. To make genetic information
available to the rest of the cell, double-stranded DNA must be transcribed into single-
stranded mRNAs and transported to the cytoplasm. In the cytoplasm, proteins are
synthesized in the translation process by ribosomes based on sequence information
stored in mRNAs. Three nucleotides make up a codon, which determines an amino
acid; a sequence of nucleotides determines amino acid sequence of a polypeptide.
The central dogma reflects how information is transferred among different molecules.
However, many exceptions to this dogma have been found. For instance, much
of the DNA is transcribed into non-coding RNAs such as microRNAs (miRNA)
that are about 22 to 26 nucleotides in length. These non-coding RNAs regulate
expression of more than 60% of the protein-coding genes in humans [20].
Proteins are functional units in molecular biology and are involved in every
biological process. Kinases are one of the most essential proteins regulating almost
all signal transduction processes [21]. Kinases are enzymes that catalyze addition
of a phosphate group to a specific substrate. Receptors are another important
group of proteins that receive and mediate chemical-signals from the extracellular
environment into cells or nucleus. Transcription factors are essential proteins
[22] that regulate transcription of genes by binding to specific DNA regions.
Transcription factors can either activate or inhibit gene transcription, and one
transcription factor can regulate multiple genes.
Gene regulation refers to the procedure of transferring information from genome to
proteins [23]; this is not always as straightforward as implied in the central dogma.
Gene regulation takes place via transcriptional and post-transcriptional regulation.
In transcriptional regulation, regulatory proteins such as transcription factors bind
to specific DNA sequences (known as transcription binding sites such as promoters
and enhancers) to transcribe mRNAs. Transcriptional regulation is considered
the most common form of controlling gene expression [23]. Small RNAs such
as miRNAs repress gene transcription at the post-transcriptional regulation stage.
miRNAs bind to target gene mRNAs to inhibit mRNA expression. Thus, miRNA
regulation is an important complement to the central dogma of molecular biology
(Figure 1).
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Figure 1: The backbone of molecular biology: The Central Dogma of Molecular
Biology. The dogma is represented by four major stages. Replication: DNA replicates
its information in this process. Transcription: DNA codes for production of RNAs
including messenger RNA (mRNA). In eukaryotic cells, mRNA is processed by
splicing, where exons are joined and introns are removed. The mRNA is then
delivered from the nucleus to the cytoplasm. Translation: mRNA that carries generic
information is used as a template to synthesize proteins.
Many cancer studies have been designed at the mRNA level [24, 25, 26, 27]. mRNA
measurement is relatively cost efficient, and mRNA quantification is relatively
accurate compared to protein expression. Moreover, mRNA expression can be
representative of protein expression to some degree [28, 29, 30]. According to
the central dogma of molecular biology, mRNA and protein expression should
be tightly correlated. While many studies have reported the correlation between
mRNA and protein expression [31, 32, 28], studies at the protein level are still
necessary, as expression of mRNAs and proteins is not always highly correlated
[29, 28]. One reason for low correlation between mRNA and protein expression
is that proteins undergo structural changes (known as protein folding) and interact
with each other, forming protein complexes. Another reason is the involvement of
post-transcriptional regulation, such as miRNA regulation [29]. miRNAs repress
protein synthesis by either silencing mRNAs or degrading mRNAs via binding to
target gene mRNAs [33].
A pathway is a collection of molecular constituents (including transcription factors,
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receptors, and small molecules) and mechanisms through which the molecular
constituents are governed, providing various functionalities [34, 8]. Pathways play
crucial roles in various physiological and cellular developmental processes [34].
Accordingly, studying pathways is essential to understanding their roles in human
diseases, such as cancer [35] and cardiovascular disease [36].
Pathway construction was hindered by the lack of advanced tools and techniques
for annotating function of unknown genes and proteins [37]. Nevertheless, the
development of cellular and molecular biology experiments and data produced
from these experiments are advancing construction of pathways and annotation
of elements in the pathways [38]. Experimental observations from the published
literature are constantly being mined to improve pathway representations [39, 34,
40]
Another way to construct pathways is to fit mathematical models on biological
molecular measurements to infer structures among genes. Many methods have
been suggested, such as Minimum Redundancy/Maximum Relevance Networks
(MRNET) [41], Weighted Gene Co-expression Network Analysis (WGCNA) [42],
and Supervised Inference of Regulatory Networks [43]. Mathematical models
provide experimentally testable hypotheses and, in return, biological experiments
test these hypotheses and provide experimental data to improve mathematical




Network science focuses on studying behaviors of real-world systems using ob-
servational data [46]. Networks can be conveniently used to represent complex
systems where components are dependent and interact with each other. Accordingly,
networks are widely used in many fields, such as technology [1], finance [47], and
biology [2, 3]. In biology, networks are applied to data from many levels of
measurements resulting in different networks, including protein-protein interaction
networks [2], metabolic networks [48], and gene regulation networks [3].
In this chapter, the basics of networks are introduced, followed by a review of
biological networks.
3.1 Network basics
In mathematics, networks have been studied under the name of graphs. A network,
or a graph G(V,E), is a collection of nodes, or vertices, V, which are connected by a
set of links, or edges, E ⊂ V×V [49]. In this study, networks and graphs are used
interchangeably. A directed network is a network where edges have a direction,
while an undirected network is a network where edges do not have orientations.
For example, if there is a biological network where vertices represent proteins and
edges indicate interactions, then this is an undirected network, as protein A and B
interact with each other. In contrast, if the vertices are genes, and there is an edge
from gene A to gene B when the product of gene A regulates the expression of gene
B, then this network is directed.
A network can have labels and attributes for both vertices and edges, such as
names, weights, and types. Vertices and edges can have, in theory, an infinite
number of labels and attributes. Attributes can be of numerical or categorical
values. Weight, which is normally a numerical attribute, is present in networks
called weighted networks. Weights denote different roles in a network. For instance,
in a biological network where vertices have a weight attribute that represents the
number of neighbors that a vertex connects to, vertices with high weights are much
more important than vertices with low weights [48].
Degree of a vertex is the number of edges that the vertex connects to, with self-
loops calculated twice [49]. There are three different types of degree (in-, out-, and
total). In-degree is the number of in-edge incidents, out-degree is the number of
out-edge incidents, and total degree is the sum of in- and out-degrees. Degree is a
non-negative value, and an isolated vertex is defined as a vertex with degree zero.




A path is defined as a number of edges that connect a sequence of vertices in a
network [49]. The number of edges in a path can be either finite or infinite. The
length of a path is measured by the number of edges in an unweighted network
or the sum of edge weights in a weighted network. In a network, it is possible to
have many alternative paths from a vertex A to another vertex B. Hence, there are
different lengths from vertex A to vertex B. A path, where the number of edges
is minimal (in an unweighted network) or the sum of its constituent edge weights
is minimized (in a weighted network), is called shortest path given two vertices.
Shortest path has many important applications, such as the well-known travelling
salesman problem where following question is asked: "A salesman is required
to visit once and only once each of N different cities starting from a base city,
and returning to this city. What path minimizes the total distance travelled by the
salesman?" [50].
3.1.2 Subnetworks
Networks can have a various number of vertices and edges, ranging from zero to
a thousand, even a million. When a network is large (e.g., 10,000 vertices), the
network can be dissected into small and tractable networks based on functionality
or structure. These dissected and small networks are called subnetworks [49]. A
subnetwork S(Vs,Es) of a network G(V,E) is defined as a network where vertices
and edges are subsets of vertices and edges of the network G [49]. Subnetworks
are particularly useful to study functionality and modularity of networks. Many
networks, including social and biological networks, exhibit a high degree of
modularity.
3.1.3 Topology
Network topology is the arrangement of vertices and edges in the network. Scale-
free and Erdős–Rényi networks are the most common topologies. The term scale-
free network, first introduced by Albert-László Barabási and his colleagues, was
used to map the topology of the World Wide Web in 1999 [51]. Many networks,
such as social and biological networks, have been found to be not random but have
features of scale-free networks [51, 52]. A key feature of scale-free networks is the
presence of a heavy-tailed degree distribution that follows a power law (Figure 2).
Formally, the distribution of scale-free networks (S(k)) are defined as below:
S(k) = A · kλ , (1)
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where A is a constant value, and k and λ are degree and a degree exponent value,
respectively. The value of λ varies depending on the network complexity. For
example, the value ranges from two to three in biological networks [52], and 2.1±
0.1 in a network with over 800 million vertices where a vertex is a document and
an edge is a connection pointing to one document from another [51]. The topology
of these networks is determined by connectivity of the networks, and hence can be
used to effectively locate the most influential molecules in the biological networks
and the most informative nodes in the World Wide Web [52, 51].
Scale-free networks have other interesting features such as clustering and hierarchi-
cal structure. A direct result of the heavy-tailed degree distribution is indication of a
limited number of vertices with degrees that are greatly over mean degree, forming
a hierarchical structure. High-degree vertices are often known as hubs and serve
specific function in networks, although the functions are dependent mainly on the
fields of research.
Scale-free networks show a stunning degree of tolerance against errors. The power
law of the degree distribution in a scale-free network implies that the majority of
vertices have only one or a few edges, and these vertices with smaller connectivity
are targeted with much higher probability when malfunctions and errors occur
randomly. Malfunctions and errors in these low-degree vertices do not dramatically
change the network structure and have little influence, as the topology of the
network almost remains the same. However, robustness against malfunctions and
errors comes at a high price, as scale-free networks are lethal to dysfunction of a
few vertices (such as hubs) that play key roles in maintaining the network structure
[53, 54, 55].
In contrast to scale-free networks, Erdős–Rényi networks, which are named after
Paul Erdős and Alfréd Rényi, have a fixed number of vertices with approximately
the same number of edges for each vertex [56] (Figure 2). Erdős–Rényi networks
are rare in reality and are not covered in this thesis.
3.2 Intracellular networks
Biological networks are used to represent and model chemical reactions in cells,
neural connections in nervous systems, and relationships between species in
ecosystems [46]. This thesis focuses on the biochemical networks that represent
interactions and regulatory mechanisms at the molecular level in biological cells. In
particular, this thesis focuses on one of the biochemical networks, gene regulation
networks. In this thesis, the biological, biochemical, or intracellular networks refer
to gene regulation networks.
8
3 BIOLOGICAL NETWORKS










Figure 2: Comparison between degree distributions of scale-free and Erdős-Rényi
networks that have an identical number of vertices and edges. Two degree distributions
are plotted on a logarithmic scale. The degree distribution of the scale-free networks
shows a linear correlation to the degree on the plot, indicating that vertices with
lower degree have higher probability. Scale-free networks also have a broad range of
degrees, suggesting inhomogeneity. By contrast, the degree distribution of Erdős-Rényi
networks peaks at the mean degree and dwindle quickly to both sides, showing that
these networks are homogeneous.
3.2.1 Pathways as subnetworks
Pathways can be represented as networks where vertices are genes and small
molecules, and edges are regulations among them. Pathways are relatively small
compared to intracellular networks, where dynamics of all molecular constituents
in a cell are modeled. Pathways are subnetworks of intracellular networks and
are assumed to be independent and isolated. Compared to intracellular networks,
pathways have advantages in studying functions and interpreting biological systems.
On the other hand, pathways normally overlap with each other at a gene or regulation
level, and the overlapping genes or regulations often display different functions in
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different pathways. Such a phenomenon is referred to as cross-talk. The small scale
and isolation of pathways limits understanding from a systems biology perspective;
pathways fail to shed light on the whole picture of biological systems.
3.2.2 Gene regulation networks
Gene regulation networks participate in many life processes, including cell dif-
ferentiation, cell cycle, and apoptosis [3]. Dynamics of gene regulation networks
govern gene expression that determines cellular architecture, enzymatic activities,
and many other properties through protein expression [23]. Thus, studying patterns
of gene regulation networks is crucial to understanding the cellular processes.
Gene regulation networks are a collection of genes and their regulations, which
work together to control gene product abundance [3]. In gene regulation networks,
genes are represented as vertices and their physical regulations (i.e., gene activations
and inhibitions) are represented as edges. Gene regulation networks are directed; a
direction from gene A to gene B indicates that gene A is a regulator and controls
expression of gene B.
A solid theory of networks provides guidance for exploring mechanisms inside
cells from biological networks. Using a network representation form of biology
systems, a various number of computational and mathematical approaches (such as
graph mining, machine learning, and statistics) can be applied to reveal a variety of
insights into biological systems.
3.2.3 Scale-free networks
Studies of topology in biological networks in different species, including humans,
have revealed that biological networks are scale-free networks, and the distribution
of degree follows power law [51, 52]. High-degree genes (i.e., hub genes) are
usually transcription factors or kinase proteins in biological networks. Hub genes
are normally the genes that have at least five neighbors or edges [55]. Hub genes
play important roles in mediating and controlling signaling flow in biological
networks. For example, there are 1895 genes and 5859 regulations in the regulation
network generated by merging all the pathways from WikiPathways [39]. The top
15 genes with highest number of neighbors are shown in Figure 3. Out of 15 genes,
12 are either transcription factors or protein kinases. TP53, which is one of the most
studied genes, has the largest degree, 90 (Figure 3). TP53 is a transcription factor
that has an important role in many anticancer mechanisms such as cell apoptosis
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Figure 3: Top 15 genes with highest degree. Degree was calculated from a cellular
network merged from WikiPathways. The network only contains gene activations or
gene inhibitions from WikiPathways. The network consists of 1895 genes and 5859
regulations between the genes.
Having the property of scale-free networks, biological networks are tolerant to
random errors, such as random mutations, but dysfunction of certain genes is lethal.
Random mutations are accumulated throughout life. These mutations are equally
distributed in the genome, and it is more likely that low-degree genes accumulate
many more mutations than high-degree genes. Hence, most people do not show
phenotypic effects even though they have several or even hundreds of mutations.
However, once mutations occur in key genes, such as hub genes, the damage is
severe. For instance, mutations in TP53 dramatically influence the overall signaling
of biological networks, as defects of TP53 lead to dysregulation of a large number
of downstream genes and hinder signaling from one gene to other genes. TP53
is mutated in about 30% of breast cancer patients [10] and in almost all (96%)
high-grade serous ovarian cancer (HGS-OvCa) patients [11].
3.2.4 Bottleneck genes
A recent study has identified another important property of biological networks,
which is a bottleneck [61]. A bottleneck measures the amount of signaling
11
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Degree high, betweenness low
Degree low, betweenness high
Degree high, betweenness high
Figure 4: Scatter plot of degree and betweenness. The network only contains gene
activations and gene inhibitions from WikiPathways. The network consists of 1895
genes and 5859 regulations between them. In the scatter plot, the X and Y axes
represent betweenness and degree, respectively. Betweenness is logarithmic based on
two. Degree and betweenness were calculated using an R package igraph [60].
information that goes through a gene. Technically, a bottleneck is evaluated by
betweenness centrality that counts the number of shortest paths passing through
a gene from all genes to all other genes. The scale of bottlenecks is between zero
to hundreds of thousands, while the median value is zero from the gene regulation
network generated using WikiPathways database. It has been demonstrated that
bottleneck genes play essential roles in controlling and mediating communication
information flow from one cluster to another [61]. Bottleneck genes are analogous
to bridges and tunnels on a highway map, while hub genes are analogous to
roundabouts and highway crossings. Hence, both bottleneck and hub genes are
crucial in biological networks.
The degree of bottleneck genes varies, ranging from 2 to 90, as measured from
WikiPathways (Figure 4). Here we define a bottleneck as a gene whose betweenness











































































































































































































Figure 5: Bottleneck role of PTEN and S1PR1. This small network is generated from
WikiPathways where PTEN, S1PR1, and their neighbors with distance smaller than
two are involved. All signals from the genes in the cluster (red ellipse) must go through
PTEN, AKT1, and S1PR1 to the genes in another cluster (green ellipse).
and bottleneck genes shows high correlation between them in general (Pearson
r =0.6; Figure 4). TP53 is not only a hub gene but also a bottleneck gene with the
largest betweenness and the highest degree. Interestingly, however, high bottleneck
genes do not necessarily have high degree, and vice versa (Figure 4). PTEN and
S1PR1 have high betweenness but low degree (Figure 4). A subnetwork of the
biological network that is related to the PTEN and S1PR1 genes with their neighbors
reveals that PTEN and S1PR1 are the main signaling mediators and controllers from
one module to another (Figure 5). S1PR1 is directly regulated by ATK1, which is
activated by PTEN. Thus, all signaling from the module (red cluster in Figure 5)
to another (blue cluster in Figure 5) must go through PTEN, AKT1, and S1PR1.
Accordingly, any malfunction in PTEN, AKT1, or S1PR1 completely destroys the




Cancer is a complex disease characterized by uncontrolled growth and spread of
abnormal cells [62]. It is one of the most lethal diseases, and cancer deaths are
predicted to rise from an estimated 8.2 million to 13 million per year worldwide by
2030. Cancer is well recognized as a disease of aging. Estimated tumorigenesis
occurs at around the 20 years of age and cancer detection at around age 50 [63].
Cancer is partially caused by lifestyle and environmental factors. Unhealthy
lifestyles, such as smoking and heavy alcohol consumption, increase the risk
of developing cancer [64, 65]. For example, tobacco smokers have a 20 times
greater risk of developing lung cancer than non-smokers and have an increased
risk of developing many other tumor types as well [66]. Increased exposure to
carcinogenic agents present in the occupational and general environment results
in an elevated risk of developing cancer. Air pollution, mainly caused by smoke
from coal consumption, contributes to a 36-40 times higher lung cancer risk than
less-polluted air [67]. Accordingly, the World Health Organization now classifies
smoke from coal consumption as a cancer-causing agent.
In this chapter, genomic alterations in cancer are introduced, followed by a discus-
sion of dysregulation of biological networks and integrative approaches in cancer.
Finally, cancer heterogeneity is examined.
4.1 Genomic alterations
Cancer is a genomic disease. While an estimated 5% to 10% of all cancers are
directly inherited from parents [68, 69], the majority of cancers happen sporadically.
Non-hereditary cancers are the focus of this thesis. Non-hereditary cancers arise
from accumulated genome instability resulting from random genomic changes [70].
Genomic alterations consist of genetic changes, such as mutations, DNA copy-
number alterations, gene expression changes, and epigenetic changes, including
histone modifications and DNA methylation.
The hallmarks of cancer [71] are largely driven by genetic and epigenetic alterations
[72, 73] through the central dogma of molecular biology. Genetic changes in cancer,
such as aberrant expression of oncogenes or tumor-suppressor genes, disturb the
protein expression leading to severe consequences. Since DNA copy-numbers are
tightly linked to mRNA expression, alterations in DNA copy-numbers change gene
expression located in the same DNA regions [74]. DNA point mutations also change
mRNA expression by affecting the binding sites of transcription factors [75, 76] or
miRNAs [77, 78]. Both DNA copy-number alterations and point mutations may
14
4 CANCER
lead to expression changes of the corresponding proteins. However, genetic changes
do not always alter gene expression but may modify protein functions via effects
on protein folding and stability [79, 80].
In addition to genetic alterations, epigenetic changes also disturb protein expression
in a similar manner by activating cancer genes or inactivating tumor-suppressor
genes. Methylation, a type of epigenetic change, plays an important role in
cancer through silencing transcription of critical growth regulators (such as tumor-
suppressor genes [81]), which subsequently promotes carcinogenesis [82]. Addi-
tionally, histone modifications (another type of epigenetic marker) are highly linked
to DNA methylation changes and control of gene activity in cancer [83, 84, 85].
Changes in proteins and their expression through either genetic or epigenetic
changes affect protein-protein interactions and gene regulation, which eventually
impacts the dynamics of biological networks. Furthermore, dysregulation of
biological networks results in disruption of fundamental biological processes such
as cell death, proliferation, differentiation, and migration [86, 87]. Hence, cancer
can be considered a disease of alterations on the biological network level, instead
of a single-gene disease [4]. Genetic changes (especially transcriptome changes)
and their effects on biological networks are the focus of this thesis.
4.2 Dysregulation of biological networks in cancer
Many forms of cancer exist, and global gene expression changes have been observed
in cancer cells compared to normal cells. However, a relatively small number of
fundamental alterations are shared by most tumor samples [71]. Mapping genomic
alterations onto the pathway level has revealed that cancer samples share more
alterations on the network level [88].
Many common pathways are altered in cancer. The cell cycle is one of the most
commonly altered pathways in various cancers, including breast cancer [10, 89],
ovarian cancer [11, 90] and diffuse large B-cell lymphoma (DLBCL) [91, 92]. The
cell cycle governs cell division and DNA replication by tightly regulating cell
cycle checkpoints. Hence, dysregulation of the cell cycle impacts cell survival and
leads to uncontrolled cell replication, which is one of the major cancer hallmarks
[71, 93]. Functional loss of the retinoblastoma gene (RB) occurs in many cancers,
and disabling pathways related to RB is essential for cancer formation due to the
tumor-suppressor role of RB [94, 95, 96]. Integrative analysis of ovarian cancer by
TCGA has shown that the RB pathway is deregulated in 67% of the tumor samples
[11]. Mitogen-activated protein kinase (MAPK) pathways, which interconnect
extracellular signals, are an evolutionarily conserved mechanism that governs
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essential biological processes such as cell growth, proliferation, migration, and
apoptosis [97].
4.3 Systematic integrative approaches in cancer
A divide and conquer approach, also known as reductionism, divides complex
biological systems into smaller and more manageable constituent parts. Such an
approach has been successful for the past 40 years to study the chemical basis and
functionality of individual genes or proteins [98]. However, biological systems
are complicated and have emergent properties that cannot always be seen on an
individual molecular constituent level. In particular, cancer phenotypes cannot be
explained by individual molecular constituents [71, 99, 100].
Systems biology was introduced about two decades ago to study holistic and
composite properties of biological systems that were undetectable by reductionism,
which cannot address the the whole picture of the system [101, 99]. Instead of
evaluating a single constituent, systems biology approaches offer simultaneous
assessment of many factors of the dynamic system across different time points and
contexts [101]. These approaches are becoming a complement to the reductionist
approaches.
High-throughput technologies with unprecedented resolution and speed have been
developed, and a large number of public high-throughput datasets have been
generated since their advent. TCGA is a publicly available repository storing
molecular and clinical data of 11,000 patients from 33 different cancer types.
In addition to TCGA, the Gene Expression Omnibus (GEO) is another public
database that contains data from more than one million samples profiled using
mostly microarray and partially next-generation sequencing technologies [102].
Rich genome-scale multi-omics datasets have provided great opportunities to study
cancer and have motivated the development of systematic approaches to analyze
and integrate the data. Important applications of integrating multi-omics data in
cancer research are identification of prognostic biomarkers and cancer subtypes and
understanding of cancer mechanisms. Prognostic biomarkers can be used to predict
patient survival, cancer subtype identification can provide improved treatments for
patients, and understanding of cancer mechanisms can improve interpretation of
cancer phenotypes [103].
Many successful applications of integrative analysis on multi-omics data have
been reported. One is the identification of subtypes in many cancers. The TCGA
consortium has identified subtypes with clinical association (e.g., patient survival)
for several cancers, including breast cancer [10] and ovarian cancer [11]. These
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subtypes were identified by integrating genetic, transcriptomic, proteomic, and
pathway data. Another successful and comprehensive analysis is the identification
of breast cancer subtypes by the METABRIC group [104]. Ten novel subgroups
were discovered using METABRIC data, where 2,000 breast cancer samples were
profiled at both the genomic and transcriptomic levels [104].
Computational integrative approaches help uncover cancer driver genes that are
partially or completely responsible for cancer phenotypes [105]. Using a computa-
tional framework to detect alterations that promote cancer progression by integrating
copy-number and gene expression data, Uri David Akavia and colleagues identified
two novel driver genes in melanoma [106]. PARADIGM is a computational tool
that determines patient-specific pathway activity by incorporating many types of
omics data [104]. PARADIGM outputs pathway-level activity for each patient
using probabilistic inference, and its utility has been demonstrated by identifying
the clinically relevant subtypes from the glioblastoma multiforme data. iPAS [107]
and Pathifier [108] are mathematic integrative approaches that transform gene-level
information to biological network-level information. Both methods analyze cancer
samples at single-patient resolution, providing biological interpretation on the
network level for each patient. Moreover, these two methods have not only revealed
clustering with patient overall survival association in glioblastoma multiforme, lung
and colorectal cancers, but also provided biological interpretation.
Clinical data play an important role in data integration. The importance of this
is shown via building survival association models [109, 110]. Integrating clinical
data to build survival models is one of the most widely used approaches. In
survival models, survival time and events are correlated with biomarkers (e.g.,
genes, proteins, pathways). It has been shown that survival models with single
molecular data provide little improvements in predicting patient survival, whereas
survival models using integrative approaches have much better predictive power
[111].
4.4 Heterogeneity in various cancers
Biological variations are any differences between species, individuals, organs, and
cells. Some biological variations are visible, such as phenotypic variations including
eye color and height. However, variations such as genotypic variations are deeply
hidden within the nucleus and are almost invisible as phenotypes. While biological
variations have created the diversity of biology and enriched our world, they also
increase challenges in health care, especially in cancer treatments. Such variation
diversity in cancer is known as cancer heterogeneity. Many cancers encompass a
number of histological and genomic subtypes.
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More detailed heterogeneity in various cancers will be discussed here: breast cancer,
ovarian cancer, and DLBCL. Breast cancer data were used in Publication I and
Publication II. Ovarian cancer and DLBCL data were used in Publication II and
Publication III, respectively.
Breast cancer is the most common cancer worldwide in females [112]. Breast cancer
is an epithelial cancer that develops from cells lining milk ducts. Heterogeneity in
breast cancer has been found in both histological and transcriptional profiles and
has been known for a long time. Four subtypes, namely TNBC, HER2+, luminal
1, and luminal 2, have been identified using immunohistochemistry based on the
expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 [13].
Five subtypes have been stratified using high-throughput gene expression data,
namely basal epithelial-like (or basal-like), HER2-enriched, normal breast-like,
luminal A, and luminal B groups [113]. There are substantial overlaps between the
TNBC and basal epithelial-like subtypes [114, 115, 116]. Subtyping can provide
improved and personalized treatments for patients from different subtypes. For
example, adjuvant endocrine therapy is used to treat ER-positive patients and leads
to a significant improvement in patient overall survival rate and reduction in relapse
[117].
TNBC is characterized by low or missing expression of ER, PR, and HER2. TNBC
is the most aggressive and invasive breast cancer subtype [17]. There are few
beneficial treatments for patients belonging to the TNBC subtype, as patients with
the TNBC subtype lack ER and PR expression as targets. Recent studies show
that the TNBC subtype can be further divided into six subgroups with different
survival associations [17, 118], which further increases the challenge of treating
TNBC patients.
Ovarian cancer is an epithelial cancer and is the fifth most lethal cancer in the
United States [112]. The estimated number of deaths per year caused by ovarian
cancer in United States is 14,180 [112]. HGS-OvCa is the most common and
aggressive ovarian cancer subtype. The five-year survival rate of the HGS-OvCa
subtype is 35% to 40% [110]. The standard therapy for the HGS-OvCa patients is
surgery and platinum-taxane combination chemotherapy. However, most patients
who undergo such a treatment relapse after 18 months [119].
HGS-OvCa is genetically characterized by ubiquitous mutations and copy-number
alterations [120]. The most common mutations occur in TP53 (96%) [11]. Germline
mutations in BRCA1 or BRCA2 are observed in more than 15% of the HGS-OvCa
patients, and it has been shown that patients with these mutations have better
chemotherapy response [121]. TCGA research has identified four subtypes in




DLBCL belongs to the category of hematological malignancies that are the most
common lymphomas in adults. The standard treatment for patients with DLBCL
is a combination of rituximab with cyclophosphamide, doxorubicin, vincristine,
and prednisone [122, 123]. Despite improved diagnosis and overall outcome of
DLBCL patients, an estimated 30-40% of patients experience relapse or resistance
to the treatments [124]. This is due to the heterogeneity that exists both among
and within the lymphoma subtypes [125, 126]. Patients with DLBCL have been
mainly classified into two subtypes, germinal center B-like cell (GCB) and activated
B-like cell (ABC) [24]. There is a substantial clinical difference between these two
subtypes in five-year survival [127]. Patients from the GCB subtype have less cancer
progression and have longer survival time than patients from the ABC subtype
[128, 129]. BCL2 is the most frequently activated oncogene in DLBCL [130]. The
phosphatidylinositol signaling system, JAK-STAT cascade, B-cell receptor (BCR)
signaling, and MAPK signaling are associated with lymphomas [131, 132].
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5 Aims of the study
My research focused on developing and applying computational methods for
integrating multi-omics cancer data. In particular, this work focused on methods
to integrate transcriptomic, pathway, and clinical data. The general aims were to
improve interpretation of transcriptomic data, to identify prognostic markers, and
to suggest tailored treatments at the single-patient level.
The specific aims of my research were to:
1. Develop a method that quantifies pathway alterations at a single-patient level
by taking pathway topology information into account.
2. Develop a method that integrates transcriptomic data and biological network
information at a single-patient level.
3. Apply network-based integrative methods to breast cancer, ovarian cancer,
and DLBCL, and to identify putative prognostic markers.
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6 Materials and methods
In this chapter, I will summarize the biological materials and computational methods
used in each of the publications in this thesis. A more detailed description of
materials and methods can be found in each publication.
6.1 Data
An overview of datasets used in my research is presented in Table 1, including
cancer types and measurement technologies. For the RNA-Seq gene expression
data from TCGA, we used gene expression quantification fully processed by TCGA.
For other data from microarray and RNA-Seq technologies, we preprocessed the
data ourselves using customized pipelines. In addition, we also used data from the
GEO repository to validate the findings from the TCGA data.
Transcriptomic data were used in Publication I, II, and III to quantify differential
expression of genes between treatment and control samples. The data were used
to study pathway alterations in the treatment samples. Transcriptomic data were
analyzed in two steps: preprocessing and differential expression calling.
The preprocessing step of gene expression microarray data consists of background
correction where background noise is removed, normalization where chip effects
biased by raw probe signals are removed, and summarization in which a set of probe
intensities are summarized forming expression of genes. Robust multi-array average
(RMA) (that has been used as a standard method) was used for the microarray data
[134].
The preprocessing step of RNA-Seq analysis consists of quality control, alignment,
and quantification. Quality control is an important step; it trims low-quality bases,














Table 1: Overview of datasets used in each publication. DLBCL: diffuse large B-cell
lymphoma; BRCA: breast cancer; OvCa: ovarian cancer. Asterisk (∗) denotes the
datasets that we processed ourselves.
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removes remaining tags or adapters from sequencing or polymerase chain reaction
(PCR), and discards reads whose length is shorter than a certain threshold. Once
this has been completed, reads are aligned to a reference transcriptome. Transcript
expression is estimated from the alignment reads. Furthermore, the estimated
transcript expression is used to quantify gene expression in the quantification step.
RNA-Seq data analysis was performed using Anduril framework, where many
sequencing-related components are implemented and customized pipelines can be
created [135, 136].
Gene expression measures the relative amount of mRNA quantification but does
not indicate if a gene is differentially expressed (DE). Accordingly, differentially
expressed genes (DEG) need to be identified. In the differential expression calling
step, groups of samples are compared to identify DEGs. One widely used statistic
is the t-test, which determines whether two groups of samples are significantly
different from one other provided that the samples follow a normal distribution.
Another commonly used statistic is fold change, which is calculated as the ratio of
two values or means of two groups. Fold change describes the amount of quantity
changes from one condition to another.
6.2 Pathway analysis methods
Pathway analysis has been widely used and has experienced three generations over
the last 15 years: over-representation analysis, functional class scoring approaches,
and pathway topology-based methods [137].
Over-representation analysis, also known as gene set enrichment analysis, was given
rise by the need to interpret high-throughput microarray data. Over-representation
analysis calculates statistics of a fraction of a predefined gene set enriched among
a list of DEGs. One of the main limitations is that over-representation analysis
methods consider each gene equally, assuming they are independent from each
other [137].
Functional class scoring approaches are an improvement of over-representation
analysis methods, and overcome several limitations of the over-representation
analysis methods. Functional class scoring approaches treat all genes in a pathway
unequally by calculating gene-level statistics. These gene-level statistics are
summarized onto pathway-level statistics [137]. One of the most widely used gene
set enrichment analysis tools is DAVID [138]. In many cases, pathways contain
important information beyond simple gene sets of pathways, such as physical
interaction information [39, 34, 40], and neither over-representation analysis nor
functional class scoring approaches can integrate such information.
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Pathway topology-based approaches are becoming popular and were developed to
overcome limitations of over-representation analysis and functional class scoring
methods. Pathway topology-based methods calculate gene-level and pathway-level
statistics similar to functional class scoring approaches. The key difference is that
pathway topology-based methods utilize the gene set of a pathway combined with
regulation information among them. A typical tool is SPIA, which introduces
pathway impact to analyze signaling pathways [139]. SPIA combines statistics
(obtained from classical gene set enrichment analysis) and pathway impact (that
measures the significance of pathway perturbation under a given condition).
6.3 Pathway databases
Moksiskaan [140] is a public database that stores pathways from different database
repositories including KEGG [34], Pathway Commons [141], and WikiPathways
[39]. Moksiskaan provides many useful application programming interfaces (APIs)
to integrate connectivity information between genes, proteins, pathways, drugs, and
other biological entities, resulting in comprehensive networks. Moksiskaan is built
under the Anduril framework [135].
WikiPathways is an open and public web platform used to curate, analyze, and
visualize biological pathways for scientific research [39]. WikiPathways supports
computational analysis of pathways by providing APIs. WikiPathways stores
pathways from different species, including humans. There were 299 human
pathways in WikiPathways when we analyzed the data in 2013.
The pathway interaction database (PID) is a freely available collection of curated
and peer-reviewed pathways [40], which are composed of human molecular signal-
ing, regulatory events, and key cellular processes. PID offers a range of features to
facilitate pathway exploration. These include browsing a predefined set of pathways,
creating networks centered on a particular cellular process of interest, and querying
lists of molecules derived from high-throughput experiments. In addition, users
can also download complete database contents in the format of extensible markup
language (XML) or Biological Pathways Exchange (BioPAX). When we analyzed
the BioPAX file, 458 pathways were saved in PID in 2015.
While pathway analysis does improve interpretation of high-throughput data, current
pathway analysis has several limitations: annotation is incomplete and inaccurate,
condition- and cell-specific information is missing, and it is unable to model and
analyze dynamic responses [137].
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6.4 Personalized cancer patient analysis
Personalized analysis is important to understand cancer mechanisms in individual
patients and to apply personalized medicine [15, 16]. One of the key steps in
personalized analysis is characterizing individual patient profiles. Patient pro-
files can be characterized on the gene expression, pathway, or network levels.
Characteristics on the gene expression level can be obtained directly from high-
throughput measurements, while pathway- and network-level characteristics must
be summarized from high-throughput measurements by integrating pathway and
network information.
A common strategy to quantify the characteristics of a cancer sample is to quantify
the difference between a particular cancer sample and control samples, representing
the relative activity of the cancer sample compared to the control samples. Control
samples normally are tissue samples from the same organ where the cancer first
developed. In an ideal case, a matched control sample, which is a normal tissue
sample from the same organ of the same patient, can be used to precisely quantify
gene-expression changes in the cancer sample. A matched control sample has
minimal biological variations compared to other tissue samples from different
patients or from the same patient but different organs. In practice, however, it is
difficult to obtain matched control samples due to cost issues or it may be simply
impossible (in the case of obtaining brain tissues) [111]. In cases where matched
control samples are available, gene expression changes can be represented using
fold changes between the cancer and the matched control samples.
In cases of missing matched control samples, accumulated control samples should
be adopted to quantify expression changes of genes in cancer samples [142, 108].
The activity of genes in a particular cancer sample can be represented by expression
changes (fold changes) between the cancer sample and the mean or median of
accumulated control samples. Z-score is used to calculate deviation of gene






where Zi j represents the activity of gene i in a particular patient j, Ei j is the
expression measurement of gene i in the patient j, and μi and σi are the mean and
standard deviation of expression of gene i in control samples, respectively.
Patient profiles on the pathway and network levels can be summarized from gene
expression changes, such as fold changes or Z-scores. Several summarizing methods
have been proposed, such as iPAS and Pathifier. Both methods take gene sets from
pathways assuming all genes in a pathway are equal. iPAS calculates an arithmetic
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mean of fold changes of all genes involved in a pathway. Pathifier derives a principal
curve for each pathway from a dataset, where both cancer and control samples are
included, and assigns a pathway-specific score to each sample. However, the roles
of genes in the pathways vary, and it is important to reflect the different roles in the
pathways when characteristics on the pathway and network levels are summarized.
Sophisticated methods not only use gene sets but also pathway topology to present
their topological roles in the pathways.
6.5 Kaplan-Meier survival analysis
In medical research, survival analysis is a strategy that answers questions such as:
what is the proportion of patients who survive over a period of time, and which
group of patients survives better when two or more groups are compared [143].
Survival analysis can be used to assess if a variable (such as a gene, a pathway, or a
subnetwork) has sufficient power to predict patient outcomes. In the case of two
groups, survival analysis evaluates if a group of patients with a variable survive
significantly longer or shorter than another group of patients that do not have the
variable. Survival time, also known as follow-up time, is the time period from a
beginning point to occurrence of an event of interest, for example the period from
cancer diagnosis to the event of relapse, metastasis, or death.
The Kaplan-Meier estimate is one of the best methods for survival analysis. The
Kaplan-Meier estimate is often used to measure the probability of patients who
live for a certain amount of time after diagnosis or treatments [144]. It is a non-
parametric statistic. Formally, the Kaplan-Meier survival function at a given time





where t is a random variable denoting survival time of a patient, nti is the number
of patients living at time interval ti, and N is total number of patients alive at the
beginning. For each time interval ti, the survival probability is calculated as the
number of patients surviving past ti divided by the number of patients at risk at
the beginning (t0). At time point t0, all patients are alive. Patients who drop out
of a study are considered as "censored". The Kaplan-Meier survival curve is a
decreasing step function, and its theoretical limits are S(0) = 1 and S(∞) = 0. The
overall probability of survival to a time point is computed by applying multiplication
of survival probabilities at all time intervals preceding that time (Figure 6).
A log-rank test is often coupled to a Kaplan-Meier estimate to test the null hy-
pothesis, which states that survival estimates in two or more groups are identical.
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Figure 6: Kaplan-Meier plot. Two groups of samples are compared. Samples from
Group 2 survive for shorter periods than samples from Group 1. The X and Y axes
represent follow-up time in years and probability of survival, respectively. The survival-
associated p-value was calculated using log-rank test.
The log-rank test compares the equality of survival estimates between groups by
calculating the expected number of events and the total number of observed events
in the groups. With k ∈ 2,3, ... patient groups, the test statistic, which follows χ2
[144], can be used to compute the significance (p-value) of the null hypothesis




In this chapter, I present the main results on the development of computational
integrative analytical methods and their applications in breast cancer, ovarian cancer,
and DLBCL. These methods include both an existing tool and novel methods that
we have developed to produce the findings in the publications. The main results
are the following: 1) PerPAS quantifies pathway activity at a single-patient level
to identify pathways that are associated with patient survival, 2) DERA integrates
transcriptomic data and biological network information at a single-patient level
to identify commonly regulated network modules, and 3) systematic integration
of multi-omics data improves data interpretation and identification of potential
therapeutic targets.
7.1 Personalized pathway analysis finds putative prognostic mark-
ers
Various cancers develop through accumulation of genomic alterations. Study of
cancer patients has revealed a great diversity of genetic and transcriptomic profiles,
which creates challenges in understanding of cancer mechanisms and treatments.
To address these challenges, we developed a novel computational method, PerPAS
(Personalized Pathway Alteration analysiS; http://csbi.ltdk.helsinki.fi/pub/
czliu/perpas) to interpret large-scale transcriptomic data and to identify altered
pathways from individual patients. PerPAS integrates transcriptomic data with
clinical and pathway data and quantifies pathway activity for each patient. PerPAS
can pinpoint important pathways that are associated with clinical features (such as
patient survival) and central nodes in the pathways.
Methodologically, PerPAS first standardizes gene expression data to control sam-
ples, indicating deviation of gene expression in a particular cancer sample from
the mean of control samples. In cases where control samples are missing from a
cohort, gene expression can be standardized to the mean of the cohort. PerPAS then
takes advantage of pathway topology information (such as hubness [53, 54, 55] and
bottleneckness [61, 55, 145]) to model gene impact on downstream genes. Finally,
gene activity is summarized on the pathway level to represent pathway activity of
each patient.
To demonstrate the performance of PerPAS and compare it to two existing methods,
synthetic and real expression data of the breast cancer patients were used. Synthetic
data provide controlled examples to demonstrate the utility of PerPAS and to
compare it to other methods, such as iPAS [142] and Pathifier [108] that both
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function on the single-patient level. We constructed three small pathways with
varying topology specifically to demonstrate the advantages of integrating topology
information to the model.
Analysis on synthetic pathways showed that PerPAS assigned various contributions
to genes in three pathways based on their topological roles in mediating and
controlling signaling. On the other hand, iPAS and Pathifier assigned equal weights
to each gene, even though it has been shown that hubness and bottleneckness play
important roles in biological networks [53, 54, 55, 61, 145].
The performance of PerPAS was then compared to iPAS and Pathifier using real
breast cancer data and was evaluated in terms of its ability to identify pathways that
are associated with patient survival. To compare PerPAS, iPAS, and Pathifier, we
selected a similar number of significantly altered pathways using different cutoffs
resulting in 40 pathways for PerPAS (adjusted p < 10−60), 40 for iPAS (adjusted
p < 10−60), and 43 for Pathifier (adjusted p < 10−140)).
PerPAS identified four pathways that were significantly associated with breast
cancer patient survival from the TCGA dataset; the association was verified in
three or all four independent cohorts. On the other hand, two survival-associated
pathways identified by iPAS were validated in one independent cohort. One
reason for the low validation rate of iPAS is that an arithmetic mean of gene
expression is computed for each pathway, and it is most likely that the averaged
gene expression tends to be zero due to the fact that the cancer pathways are
composed of overexpressed (positive) and underexpressed (negative) genes. These
positive and negative values have more biological meaning than mathematics.
Many pathways were thus overlooked by taking the average of gene expression,
which neutralized overexpression and underexpression effects. Moreover, due
to employing the arithmetic mean of gene expression, iPAS is easily affected by
outliers, as all genes are assumed to be equal in the pathways.
Pathifier identified seven survival-associated pathways in the TCGA cohort, how-
ever, their associations were not validated due to lack of control samples in the
independent cohorts (the main drawback of Pathifier). A requirement for control
samples in Pathifier limits its flexibility in many applications. In many cases, it
is challenging to obtain control samples. For example, it is rare to have reference
brain tissues in glioblastoma multiforme studies.
It was surprising to observe that there was only one overlapping pathway between
PerPAS and iPAS, one between iPAS and Pathifier, and none between PerPAS and
Pathifier. While taking pathway topology into account is the main reason for the
discrepancy between PerPAS and iPAS or Pathifier, it is not the only reason as there
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Figure 7: Pathway activity score distributions of a pathway with different numbers of
outliers. The X axis denotes pathway activity scores and the Y axis denotes density.
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that PerPAS, iPAS and Pathifier produced almost exclusive results, we analyzed the
tolerance of the three methods to outliers. We randomly selected 100 treatment and
100 control samples and introduced zero to four outliers to each treatment sample.
These outliers were randomly assigned to genes in a pathway that consisted of 41
genes. The pathway activity scores for the particular pathway were calculated using
PerPAS, iPAS, and Pathifier.
The density distributions of pathway activity scores by PerPAS did not show clear
mean shifting or shape changing until the number of outliers was increased to three
(Figure 7). However, the density distribution with one outlier was significantly
shifted from that with zero outliers in the Pathifier analysis; density became a
bimodal distribution when there were two or more outliers in the iPAS scores.
Furthermore, a Kolmogorov-Smirnov test was applied to statistically confirm our
observation. The statistical test compared the distribution of pathway activity scores
without any outliers to the distributions with different numbers of outliers. The
results showed that there were no significant statistical differences until there were
up to four outliers in the PerPAS scores (Table 2). The Pathifier results showed
significant differences for all comparisons; the iPAS results showed significant
differences already with two outliers. These results suggest that outliers have a
greater effect on pathway activity scores for iPAS and Pathifier than PerPAS, and
tolerance to outliers may be another major reason for the discrepancy between
PerPAS and iPAS or Pathifier. The tolerance to outliers may also be the main reason
for poor reproducibility in iPAS.
As an example of a PerPAS study, we comprehensively studied the PLK1 signaling
events pathway. The PLK1 signaling events pathway was significantly altered in
tumor samples compared to control samples. The mean activity score in cancer
samples was 3.4 times greater than that in control samples. Our patient survival
association study showed that patients with high activity of the PLK1 signaling
events pathway exhibited poorer survival than patients who a had lower alteration
of this pathway, suggesting its prognostic value in breast cancer. This survival
Methods One outlier Two outliers Three outliers Four outliers
PerPAS 0.99 0.58 0.09 0.02
iPAS 0.21 2.25E-07 9.57E-06 7.82E-09
Pathifier 1.87E-08 7.80E-02 7.87E-04 4.96E-07
Table 2: Statistical comparison of distributions between pathway activity scores with
and without outliers. A Kolmogorov–Smirnov test was used to test the equality of
probability distributions. The distribution of pathway activity scores without any
outliers was compared to the pathway activity scores with one to four outliers.
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association was validated in all four independent cohorts. The prognostic value of
the PLK1 signaling events pathway was compared to the PLK1 gene which has its
own prognostic value. The results showed that the PLK1 signaling events pathway
had improved prognostic value compared to the PLK1 gene alone (Table 3).
By further examining the pathway topology, we observed that the PLK1 gene medi-
ates and controls more than a quarter of signaling, which indicates its central role in
this pathway. PLK1 regulates many known cancer genes, including oncogenes AU-
RKA [146] and ECT2 [147] and tumor-suppressor gene STAG2 [148]. Furthermore,
we found that PLK1 expression was highly correlated with its downstream genes,
suggesting that PLK1 might directly regulate these downstream genes in the breast
cancer patients. The central role of PLK1 and its high correlation with downstream
genes make it a promising and effective therapeutic target. By inhibiting expression
of PLK1, cancer progression might be repressed. Indeed, PLK1 is an oncogene
[149] and both phase I and II studies of PLK1-inhibitory compounds have been
conducted [150, 151, 152]. This particular example highlights the potential of
PerPAS in providing clinically relevant findings and suggesting putative targets.
To summarize, PerPAS quantifies pathway activity at the single-patients level.
PerPAS takes pathway topology into account to score pathway activity. It cap-
tures aberrance of pathways compared to control samples and identifies pathways
associated with clinical data. We have shown that PerPAS has a much higher
validation rate of survival-associated pathways than iPAS or Pathifier. We have
further demonstrated that PerPAS can identify both key prognostic pathways and
putative therapeutic genes.






Table 3: Survival association comparison between the PLK1 gene and the PLK1




7.2 Patient-specific regulation networks enable personalized anal-
ysis
DERA (Differentially Expressed Regulation Analysis; http://csbi.ltdk.helsinki.fi/
pub/czliu/DERA/) is a novel network approach for integrating biological networks
with transcriptomic and clinical data. DERA takes analysis of gene expression
data onto the biological network level. Instead of gene sets or individual pathways,
where genes across different canonical pathways are interconnected, DERA is able
to identify biological network modules that are associated with phenotypes.
DERA first identifies DEGs for each patient and generates patient-specific regula-
tion networks (PSRN) for each patient, by overlaying gene activity status on top
of the biological network. Subsequently, these PSRNs are used to identify core
differentially expressed regulations (DER) that share similar molecular functions
between patients. DERA considers a DER as a core DER if it is identical in at least
F% of all patients. A feature of DERA is a particular fit for analyzing small- or
medium-size data that is challenging for many statistical methods where a large
number of samples are required. Two types of input data are required in DERA,
gene expression data and clinical information (e.g., group or subtype information).
The output is a set of core DERs that are phenotype-specific.
We tested DERA with 522 tumors from the TCGA breast cancer microarray cohort,
in which 59 control samples were available. The findings were verified in the
TCGA breast cancer RNA-Seq cohort, where patients did not overlap with the
microarray-profiled patients and the GEO cohort (Table 4). In this case study, we
used an F value of 50 in the discovery set; thus DERs must be found and identical
in at least 50 % of PSRNs to be categorized as core DERs. A slightly lower F
value of 40 % was used because of a smaller size in the GEO cohort. To identify
unique regulations that might drive poor prognosis and aggressiveness in TNBC, we
compared the core DERs identified from TNBC to those from the other subtypes.
DERA identified 110 core DERs from 55 TNBC samples. Their existence was
verified in one or both of the validation sets. Out of 110 core DERs, 22 were
validated in both cohorts. These 22 DERs were enriched in cancer-related pathways,
such as cell cycle and prostate cancer pathways. 110 core DERs were from different
canonical pathways, and the cross-talk issue was overcome. For instance, four
pathways (Myometrial Relaxation and Contraction Pathways, Oxidative Stress,
Corticotropin-releasing hormone, and TGF-β Signaling Pathway) were connected
by FOS, suggesting that the connection between canonical pathways would have
been unnoticed by just studying individual pathways.
Hierarchical clustering of breast cancer patients from both the TCGA and GEO
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Discovery set Validation set
TCGA_array (n) TCGA_seq (n) GEO (n)
TNBC 55 56 17
HER2 23
462 26Luminal 1 219
Luminal 2 69
Controls 59 52 7
Total 425 570 50
Table 4: Characteristics of breast cancer datasets. Subtyping is based on
immunohistochemistry of ER, PR, and HER2 expression. TNBC: ER-, PR-, and
HER2-; HER2: ER-, PR-, and HER2+; Luminal 1: ER+/PR+ and HER2-; Luminal 2:
ER+/PR+ and HER2+; Controls: normal breast tissues.
cohorts showed that the genes from 110 core DERs distinguished the TNBC patients
from patients with the other subtypes. This result indicates that potential prognostic
markers or even drug targets can be derived from these core DERs. Hence, we
refined DERs that were unique to TNBC, resulting in 31 DERs. Many of these
regulations are related to proliferation, progression, and overall survival in cancer.
FOXA1 is an independent predictor of breast cancer survival and is negatively
correlated with tumor size and grade [153]. We found that XBP1 and its regulator
FOXA1 were underexpressed in the TNBC samples, but overexpressed in the other
subtypes. FOXA1 was strongly and positively correlated with XBP1 (Pearson
r =0.83). We also found that the regulation between FOXA1 and XBP1 was
associated with breast cancer overall survival; this association was verified in the
validation set.
The most interesting regulation was the upregulation of CCNE1 by SKP2. CCNE1
is a prognostic marker in ER-negative tumors [154], and SKP2 is an oncogene in
breast cancer [155]. We found that CCNE1 was over-expressed in almost all cancer
samples compared to control samples, and the gene expression change in TNBC
was even higher compared to the other subtypes. Additionally, SKP2 was highly
expressed only in the TNBC and HER2 subtypes, but not in the luminal 1 or luminal
2 subtypes. These results indicate that higher proliferation and poorer survival in
TNBC might be driven by CCNE1 upregulation, accelerated by further activation of
its regulator SKP2. Hence, SKP2 could be a therapeutic target, and SKP2 inhibition
might control cancer cell proliferation and reduce cancer cell survival in TNBC.
Indeed, an SKP2-inhibitory compound has been identified, and SKP2 inhibition
results in significantly reduced cancer cell proliferation and survival in prostate and
lung cancer cells [156].
The utility of our approach was further demonstrated by applying DERA to ovarian
cancer gene expression data from TCGA. The application of DERA to ovarian
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cancer showed that our method had very high reproducibility. Out of 95 regulations
that were identified in the discovery set, 87 (92%) were verified in the validation set.
By comparing regulations identified in ovarian cancer and TNBC, we demonstrated
that ovarian cancer and TNBC are similar on the molecular level [10].
We also compared DERA with GSEA and SPIA, which are commonly used for
pathway analysis. The comparison showed that DERA had a much better validation
rate and higher sensitivity in a small group of samples than GSEA and SPIA.
Our main conclusion is that DEGs connect to each other and work synergistically,
dysregulating biological networks in breast and ovarian cancers. DERA identified
regulations specific for TNBC and suggested a prognostic marker and a therapeutic
target for TNBC. Our network-based integrative findings in ovarian cancer gained
additional support from the original study on the TCGA data [11]. In conclusion,
DERA is capable of identifying solid and potentially clinically valuable regulations,
and is comparable with other existing methods.
7.3 Integrative approach interprets transcriptomic data from pa-
tients with diffuse large B-cell lymphoma
Integration of multi-omics data is essential to understanding biological processes
and mechanisms behind aggressive and progressive cancer phenotypes [157]. To
identify potential novel therapeutic targets for relapsed DLBCL patients, we
integrated RNA-Seq data from seven paired primary-relapsed samples profiled
on the miRNA and mRNA levels. In addition, we used pathway information to
identify major pathways associated with cancer progression and survival, and key
genes to target.
We found that 13 miRNAs were significantly differentially expressed in the relapsed
samples compared to the paired primary samples, suggesting that miRNA expres-
sion profiles were quite similar in the primary and relapsed samples. Out of 13 DE-
miRNAs, five were excluded from the validation due to undetectably low expression
by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR)
or absence of functional primer pairs. Expression of eight DE-miRNAs was tested
using qRT-PCR on additional samples, which included 16 matched primary and
relapsed DLBCL samples. Five were significantly differentially expressed by qRT-
PCR in the primary–relapsed pairs. Many have been reported to suppress tumor
growth, invasion, and metastasis, such as miR-381-3p [158], miR-409-3p [159, 160],
and miR-493-3p [161, 162]. These reports are consistent with our findings. We
found that all five miRNAs were underexpressed in the relapsed samples compared
to the paired primary samples, which suggests a lower suppressive effect of these
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miRNAs on tumor growth, resulting in tumor growth promotion in the relapsed
samples.
To further understand the functional and mechanical roles of the DE-miRNAs,
pathway analysis was performed on the target genes of the DE-miRNAs [139].
Given the fact that miRNAs negatively regulate target gene expression [163], we
analyzed the correlation between miRNA and transcript expression in seven paired
primary-relapsed samples, and subsequently predicted the target genes of 13 DE-
miRNAs. We used SPIA for pathway analysis [139].
In total, 1088 transcripts from 787 genes were identified as potential targets of
the 13 DE-miRNAs. These 787 target genes were significantly enriched in the
pathways related to cancer, such as JAK-STAT cascade, BCR signaling, MAPK
signaling, and phosphatidylinositol signaling system. The JAK-STAT cascade has
been proposed as a therapeutic target in many tumors [164], such as hematological
malignancies [165, 166]. Recent studies also show that the BCR signaling pathway
plays an important role in DLBCL pathogenesis [167]. Targeting MAPK signaling
inhibits lymphoma cell growth in vitro and in vivo [168, 169].
To identify key prognostic markers from the enriched pathways, we tested patient
overall survival association using the Kaplan-Meier analysis combined with the
log-rank test. We performed survival analysis on the Cancer Genome Charac-
terization Initiative (CGCI) (n = 92) cohort [24] as the discovery set and the
Lymphoma/Leukemia Molecular Profiling Project (LLMPP) cohort (n = 233) as
the validation set. For survival association, we selected 28 genes targeted by the
DE-miRNAs that were enriched in the phosphatidylinositol signaling system, BCR,
and MAPK signaling pathways. Out of these 28 genes, six genes were significantly
associated with patient overall survival. Two genes, IMPA1 and PIP5K1A, were
verified in the validation set.
Five DE-miRNAs were underexpressed in both RNA-Seq and qRT-PCR measure-
ments. Hence, negative regulatory roles of these DE-miRNAs in the relapsed
samples might contribute to higher activity of pathways and further result in
cancer relapse and drug resistance. We focused on miR-370-3p and miR-409-
3p, which might be regulators in BCR signaling, MAPK signaling pathway and
the phosphatidylinositol signaling system. First, we validated four predicted target
genes of miR-370-3p using qRT-PCR. Elevated expression of miR-370-3p induced
underexpression of SYK, PIK3R1, PIK3CD, and MAPK1 genes. Next, by studying
the effect of miR-370-3p and miR-409-3p on the proliferation of DLBCL cells, we
observed that coexpression of miR-370-3p and miR-409-3p suppressed cancer cell
growth in both ABC and GCB types. Taken together, our clinical and functional
study demonstrated that underexpressed miRNAs regulate key cell survival and
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drug-resistant pathways in relapsed DLBCL samples via degradation of the mRNAs
of the target genes.
In conclusion, integration of miRNA, mRNA expression, and pathway data enables
us to identify novel potential therapeutic targets and to interpret the underlying
mechanisms. We identified five DE-miRNAs from RNA-Seq data and verified their
expression using qRT-PCR from the primary-relapsed pairs. Target genes of the DE-
miRNAs were significantly enriched in the pathways related to lymphoma, including
phosphatidylinositol signaling system, JAK-STAT cascade, BCR signaling, and
MAPK signaling [132, 131]. Two miRNAs, miR-370-3p and miR-409-3p, were
shown to contribute to cancer progression, and activation of miR-370-3p combined
with miR-409-3p significantly suppressed tumor cell growth in vitro. We also
identified two prognostic markers that were significantly associated with DLBCL
patient overall survival.
7.4 Unpublished results: PerPAS simplifies integration and facil-
itates interpretation of results
Integrative analysis of multi-omics data provides a means of comprehensively
understanding mechanisms behind complex phenotypes. Using typical methods,
i.e., strategy, statistics, and pathway tool SPIA, integrative analysis has shown
potential in identifying prognostic markers and understanding cancer relapse
mechanisms (Publication III). In addition, PerPAS identifies altered pathways
that are associated with clinical features, and stratifies cancer samples by taking
pathway topology information into account (Publication I). To study the role of
PerPAS in the integrative analysis approach, PerPAS was applied to DLBCL data.
This data contained seven pairs of primary-relapsed samples profiled on both the
mRNA and miRNA expression levels. In this study, SPIA was replaced by PerPAS,
and integrative analysis using PerPAS focused on the 13 DE-miRNAs identified in
Publication III.
We used PerPAS to score pathway activity for each sample using mRNA expression
data, and Pearson correlation was adopted to evaluate the anti-correlation role of
miRNAs to pathway activity. Out of 443 pathways, 21 pathways that were strongly
correlated with the 13 miRNAs (absolute mean of correlation r > 0.4) were selected.
As expected, many pathways were highly negatively correlated with the 13 miRNAs
and related to cancer, such as cell cycle, mTOR signaling, and p75(NTR)-mediated
signaling pathways. The strongest negative correlation was observed in the cell
cycle pathway. Out of the 13 DE-miRNAs, seven miRNAs were strongly correlated
with the cell cycle pathway (Pearson correlation r <−0.5); two had even higher
correlations (miR-1226-5p, miR-4664-5p; Pearson correlation r <−0.7). Out of
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these seven miRNAs, five were validated using qRT-PCR in the validation set
(Publication III).
Unsupervised hierarchical clustering of correlations between the 21 pathways and
the 13 miRNAs revealed distinguishable clusters (Figure 8). Interestingly, the group
of seven miRNAs was highly anti-correlated with a set of pathways forming a
cluster (Figure 8). Some of these pathways (such as cell cycle [10, 89], g-secretase-
mediated ERBB4 signaling [170, 171], p75(NTR)-mediated signaling [172, 173],
and DCC-mediated attractive signaling pathways [174, 175]) are known to be
related to diseases. The cluster where the seven miRNAs were strongly correlated
with the six pathways indicates that one miRNA regulates different pathways and
one pathway can be regulated by multiple miRNAs. Furthermore, multiple miRNAs
may synergistically regulate a set of pathways [20]. Among the seven miRNAs,
five were validated using qRT-PCR in the validation cohort (Publication III).
We concluded that miR-370-3p combined with miR-409-3p suppresses DLBCL
cell growth in vitro (Publication III). However, the mechanisms behind DLBCL
cell growth inhibition via miR-370-3p and miR-409-3p overexpression is unclear.
Integrative analysis of DLBCL using PerPAS instead of SPIA shows that miR-370-
3p and miR-409-3p are clustered together and negatively correlated with a list of
pathways. This indicates that complete inhibition of DLBCL cell progression cannot
be achieved through activation of a single miRNA but is feasible via overexpression
of a combination of miRNAs. Hence, this analysis suggests that overexpression of
all seven miRNAs may lead to better inhibition, as alternative miRNA regulations
are blocked.
Compared to the integrative analysis used in Publication III, PerPAS provides a
higher level of integration by simplifying integration steps and reducing the number
of arbitrary thresholds. Instead of identifying correlated genes with DE-miRNAs
first and then identifying significant pathways enriched by the correlated genes,
miRNA expression was directly correlated with pathway activity. PerPAS uses
only one threshold (correlation cutoff), while the typical integrative analysis uses
two thresholds (correlation and p-value cutoffs). In addition, PerPAS can identify
modules that can facilitate interpretation of complex mechanisms. For example,
PerPAS provided evidence for alternative regulations of miRNAs to the pathway
cluster. Using typical integrative analysis, however, we failed to decipher the
mechanisms where overexpression of both miR-370-3p and miR-409-3p leads to
DLBCL cell growth reduction. Furthermore, PerPAS can provide a rationale based
on statistical measurements between pathways and miRNAs, while SPIA analysis
provides a list of differentially expressed pathways without providing statistical





























































































TRAF6 Mediated Induction of the antiviral cytokine IFN alpha/beta cascade
g secretase mediated ERBB4 signaling pathway
Cell_Cycle
RNA Polymerase I Transcription Initiation
p75(NTR) mediated signaling




Transport of Ribonucleoproteins into the Host Nucleus
Regulation of Telomerase
Telomere Extension By Telomerase
Removal of DNA patch containing abasic residue
regulation of eif2
amb2 Integrin signaling
Processive synthesis on the C strand of the telomere
Aurora A signaling
2 LTR circle formation
mechanism of protein import into the nucleus
Validated targets of C MYC transcriptional activation









Figure 8: Top 21 pathways correlated with 13 miRNAs. Pathways were selected
based on their absolute correlation mean with 13 miRNAs (absolute mean of correlation
r > 0.4). In the heatmap, rows and columns represent pathways and miRNAs,





Cancer is a heterogeneous disease with characteristics of uncontrolled growth and
spread of abnormal cells. Understanding the mechanisms that drive tumorigenesis
and drug resistance requires integration of multi-omics data on the single-patient
level [176]. Personalized integrative analysis of multi-omics data provides a means
to accurately interpret data and to generate solid hypotheses for each patient. This
thesis is composed of two parts: the development of novel computational integrative
analytical methods to facilitate cancer research and application of these methods
to cancer data. In this thesis, I have demonstrated that integrative analysis of
biological networks can personalize analysis of heterogeneous cancer samples,
identify potential prognostic cancer markers, stratify cancer patients, and improve
interpretation of multi-omics data.
Recently, network-based integration approaches have been introduced to substan-
tially advance cancer studies, such as prediction of cancer outcomes [2], identi-
fication of potential therapeutic targets [86], and drug development [177]. Thus,
more attention has been directed towards development of powerful network-based
integrative methods for multi-omics data [5, 9, 178]. Two novel computational
network-based integrative methods, PerPAS and DERA, were developed. In this
thesis work, these methods exhibit a novel way to integrate gene expression data and
biological networks (Publications I and II). PerPAS and DERA take gene expression
analysis onto the pathway and network levels, respectively. Both methods aim to
analyze multi-omics data on the single-patient level, which has been a challenge in
cancer research but is a fundamental step towards personalized medicine [179].
PerPAS was applied to both synthetic and biological gene expression data to
demonstrate its utility and performance (Publication I). Application of PerPAS to
synthetic data shows that PerPAS is able to integrate pathway structure information
to present topological roles of genes in the pathways. The case study of PerPAS
on breast cancer gene expression data demonstrated that our method can identify
survival-associated biomarkers on the pathway level (which has greater significance
compared to molecular biomarkers) and can pinpoint promising targets, such as
PLK1, in the pathways. When PerPAS was compared to iPAS and Pathifier, the
relative performance of these methods was different although all three methods
seek to achieve personalized pathway integration [142, 108]. Interestingly, the
comparison of the results yielded almost exclusive pathway lists. A detailed
comparison among these methods indicated that the higher tolerance of PerPAS to
outliers comes from introduction of more information, which illuminates the need
for comprehensive data integration.
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In addition to integrating miRNA, gene expression, pathway, and clinical data
(unpublished results), PerPAS can be used to integrate genetic data to study
effects of genetic mutations on the pathway level for each patient and to provide
interpretation of genetic mutations. Another potential application of PerPAS is
to quantify pathway activity at a single-cell level to study clonal evolution in
cancer [180, 181]. In the future, PerPAS could be improved by creating more
sophisticated quantifications of gene contribution to pathways. For example, all
paths between nodes in a pathway can be used to calculate bottleneck roles, and
non-direct downstream genes can be included to quantify hub roles.
Application of DERA on breast and ovarian cancers demonstrated that DERA can
identify biomarkers on the network module level, which can subsequently be used
to stratify patients and to generate associations with patient survival (Publication
II). DERA overcomes the issue of cross-talk between pathways by fusing canonical
pathways into a biological network. Instead of individual canonical pathways,
DERA identifies network modules that are specific for phenotypes. Identification
of network modules provides improved interpretation and precise targets for cus-
tomized treatments. Indeed, many efforts have been devoted to identify biomarkers
on the network-module level. DEAP identifies the most differentially expressed
regulatory pattern in the pathways by including pathway structure information
[182]. PATHOME detects differentially expressed subpathways by evaluating the
significance of differentially expressed paths [183]. Emerging community efforts
offer increasing opportunities for improving data integration on the network level.
The DERA method can be improved by identifying connected subnetwork modules
instead of individual regulations. An improved DERA can be used to discover
novel network modules that may be associated with phenotypes, such as patient
survival and mutation status, and to provide new interpretation of results and novel
therapeutic treatments for individual patients.
Despite the similar objectives of PerPAS and DERA, these methods are fundamen-
tally different. First, PerPAS integrates gene expression and pathways while DERA
integrates gene expression and biological networks. Second, PerPAS identifies
biomarkers associated with clinical features on the pathway level, whereas DERA
identifies biomarkers on the single-regulation level. Biomarker identification on
the pathway level using PerPAS improves interpretation of mechanisms, as the
functions of most pathways are known. In contrast, the ability of DERA to identify
biomarkers on the regulation level provides more precise targets for biological
hypothesis testing. Third, PerPAS summarizes pathway activity for each patient
using all genes involved in a pathway and assumes that all genes contribute to
pathway activity unequally. DERA, on the other hand, first identifies DEGs for
each patient and uses these DEGs to infer patient-specific regulation networks.
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A comprehensive integration approach was applied to decipher the relapse mecha-
nisms in DLBCL and to provide predictive and potential therapeutic biomarkers
(Publication III). In this study, miRNA and mRNA expression data from paired
primary-relapse samples were used, which were valuable as it is challenging to
obtain cancer samples from different stages from the same patient. We identified
potential therapeutic miRNAs, such as miR-370-3p and miR-409-3p, which con-
tribute to DLBCL progression by regulating cell survival pathways and affecting
chemosensitivity. It has been shown that miRNAs are involved in the development
and progression of many cancers, including DLBCL. miRNAs are also used as
biomarkers for both prediction and prognosis [184, 185]. Some miRNAs are
associated with the DLBCL subtypes and patient survival [186, 187, 26]. However,
the potential regulation role of miRNAs in drug resistance and progression in
the DLBCL patients is unknown. Our results demonstrated that the miRNAs are
clustered and synergistically regulate a set of pathways to drive drug resistance and
progression, which would have gone unnoticed without integration of multi-omics
data.
All network-based methods presented in this thesis (PerPAS, DERA and SPIA) can
integrate multi-omics data to gain insights into complex biology systems. However,
they are limited by current biological network databases. It is essential to create
high-resolution, accurate, and comprehensive biological network databases with
detailed contextual information, such as tissue types and experimental conditions
[137, 8]. With advances in high-throughput technologies, high-resolution genomic
and proteomic data can be generated. However, the current biological network
databases only contain gene-level interactions, and higher resolution such as
transcript-level annotation is needed as a gene can be transcribed into many
different transcripts, the products of which play roles in biological networks [188].
Regulations, interactions, and pathways are experimentally curated in different
tissues under different conditions, hence contextual information is useful to interpret
results and to reduce noise. Biological networks are far from complete, but they
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